Literature DB >> 11304936

Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.

D Kwon1, J B Chae, C W Park, Y S Kim, S M Lee, E J Kim, I H Huh, D Y Kim, K D Cho.   

Abstract

The inhibitory effects of IY-81149 (2-[[(4-methoxy-3-methyl)-2- pyridinyl]methyl-sulfinyl]-5-(1H-pyrol-1-yl)-1H-benzimidazole, CAS 172152-36-2), a newly developed proton pump inhibitor (PPI) on gastric acid secretion were investigated in vitro and in vivo. In rabbit parietal cell preparation, IY-81149 irreversibly inhibited H+/K(+)-ATPase in dose-dependent manner with an IC50 of pump inhibitory activity of 6.0 x 10(-6) mol/l and that of omeprazole (CAS 73590-58-6) was 1 x 10(-4) mol/l at pH 7.4. On cumulation of 14C-aminopyrine in histamine stimulated parietal cells, the IC50 of IY-81149 was 9.0 x 10(-9) mol/l and that of omeprazole was 1.9 x 10(-8) mol/l. The inhibition rates of IY-81149 and omeprazole at a concentration of 1 x 10(-9) mol/l in human parietal cells were 137% and 64%, respectively. In pylorus-ligated rats, IY-81149 showed a 2-3 times stronger inhibitory activity than omeprazole against gastric acid secretion. The ED50 of IY-81149 and omeprazole administered intraduodenally was 1.6 mg/kg and 3.8 mg/kg. In the case of oral administration, the ED50 of IY-81149 and omeprazole was 1.94 mg/kg and 5.64 mg/kg, respectively. But after 24 h administration, the anti-secretory activity of IY-81149 was lower than that of omeprazole at all doses tested. In anesthetized rats, IY-81149 dose-dependently increased gastric pH which was lowered by histamine infusion. In the case of i.v. injection, the ED50 of IY-81149 and omeprazole was 1.2 and 1.4 mg/kg and in the case of i.d. administration, the ED50 of IY-81149 and omeprazole was 3.9 and 4.1 mg/kg, respectively. IY-81149 also significantly inhibited pentagastrin-stimulated gastric secretion. Its ED50 was 2.1 mg/kg and that of omeprazole was 3.5 mg/kg with i.d. administration. In the case of i.v. injection, IY-81149 was equipotent to omeprazole. IY-81149 also inhibited gastric acid secretion strongly in fistular rats. The ED50 of IY-81149 administered intraduodenally was 0.43 mg/kg and that of omeprazole was 0.68 mg/kg. In Heidenhain pouch dogs, the acid output was completely blocked at 0.3 mg/kg, 135 min after i.v. administration. Omeprazole showed a similar effect as IY-81149. The histamine induced increase of acid output in the Heidenhain pouch dog was blocked by 71% 150 min after oral administration of enteric-coated IY-81149 at a dose of 3 mg/kg, and omeprazole showed similar effects. In conclusion, IY-81149 revealed the characteristics as a strong proton pump inhibitor, and its potency against gastric acid secretion was superior to that of the reference drug, omeprazole.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11304936     DOI: 10.1055/s-0031-1300026

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  5 in total

1.  Intravenous ilaprazole is more potent than oral ilaprazole against gastric lesions in rats.

Authors:  Gang Yu; Xin-Qiang Lu; Rui-Bin Su; Ze-Hui Gong; He-Zhi Xie; Hai-Tang Hu; Xue-Mei Hou
Journal:  Dig Dis Sci       Date:  2014-05-07       Impact factor: 3.199

Review 2.  Efficacy of ilaprazole in the treatment of duodenal ulcers: a meta-analysis.

Authors:  Xi-Qing Ji; Jun-Feng Du; Gang Chen; Guang Chen; Bo Yu
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

3.  Pharmacokinetics, Pharmacodynamics and Safety of Multiple-Infusion Ilaprazole in Healthy Chinese Subjects.

Authors:  Hongyun Wang; Liwei Lang; Ning Ou; Ruihua Shi; Haitang Hu; Pei Hu; Ji Jiang
Journal:  Clin Drug Investig       Date:  2016-06       Impact factor: 2.859

4.  Identification of the New In Vivo Metabolites of Ilaprazole in Rat Plasma after Oral Administration by LC-MS: In Silico Prediction of the H+/K+-ATPase Inhibitor.

Authors:  Guiqiu Zhang; Kaijing Guo; Pengfei Wang; Yingbo Shan; Chen Ma
Journal:  Molecules       Date:  2021-01-16       Impact factor: 4.411

5.  Accelerating Development of Benziamidazole-Class Proton Pump Inhibitors: A Mechanism-Based PK/PD Model to Optimize Study Design with Ilaprazole as a Case Drug.

Authors:  Ranran Jia; Fan Zhang; Ni Wu; Wen Xu; Huitao Gao; Bo Liu; Hongyun Wang
Journal:  Pharmaceutics       Date:  2021-03-15       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.